Ruimin Pan
About Ruimin Pan
Ruimin Pan is a Research Scientist at NYU Langone Health, specializing in epitope mapping and immunotherapy research.
Current Position at NYU Langone Health
Ruimin Pan is currently a Research Scientist at NYU Langone Health. She has held this position since 2010. Her work is based at 550 First Ave, where she engages in advanced research in immunotherapy and vaccines.
Previous Roles at NYU Langone Health
Before becoming a Research Scientist, Ruimin Pan served as a Postdoctoral Fellow at NYU Langone Health between 2006 and 2009. During her tenure, she was involved in significant research activities, laying the groundwork for her future endeavors within the organization. This role was also based at 550 First Ave.
Research and Development Experience at Disai Biopharmacy
Ruimin Pan worked as a Research and Development Staff at Disai Biopharmacy Co., Ltd from 1999 to 2000. During this time, she was based in Xi'an, China, where she contributed to the company's biomedical research projects.
Educational Background in Cellular and Molecular Biology
Ruimin Pan earned her Ph.D. in Cellular and Molecular Biology from Sun Yat-Sen University, where she studied from 2000 to 2005. Her academic training laid the foundation for her expertise in epitope mapping and immunotherapy research.
Specialization in Epitope Mapping
Ruimin Pan specializes in epitope mapping of broadly neutralizing antibodies using ELISA techniques. This area of expertise is crucial for identifying specific regions on antigens that antibodies can bind to, helping in the design of effective vaccines and therapeutic agents.
Structure-Based Immunogen Design for HIV/AIDS
Ruimin Pan is engaged in structure-based immunogen design specifically for HIV/AIDS vaccine development. Her research focuses on creating structured immunogens that can elicit a strong immune response against the HIV virus.
Immunotherapy Research for Alzheimer's Disease
Ruimin Pan is involved in immunotherapy research aimed at treating Alzheimer's disease. Her work includes the cloning, purification, and engineering of antibodies to potentially slow down or halt the progression of this neurodegenerative disease.